Company News

March 27, 2023

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases

May 31, 2022

First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

April 12, 2022

Secarna Pharmaceuticals’ strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

February 22, 2022

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

November 10, 2021

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies

October 26, 2021

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases

October 25, 2021

Secarna Pharmaceuticals has initiated a transnational scientific consortium to identify new biomarkers for personalized cancer immunotherapy with ASOs

October 05, 2021

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus™-based ASOs to effectively treat diabetic kidney disease

September 02, 2021

Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery

August 05, 2021

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity


BIO International Convention

Boston, MA, USA

June 5-8, 2023

Media Contact

MC Services AG
This email address is being protected from spambots. You need JavaScript enabled to view it.